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Abstract 28 
Bioreactors are crucial tools for the manufacturing of living cell based tissue engineered 29 
products. However, to reach the market successfully, higher degrees of automation as well 30 
as a decreased footprint still need to be reached. In this study, we assessed the use of a 31 
benchtop bioreactor for in-vitro perfusion culture of scaffold based TE constructs. A low 32 
footprint benchtop bioreactor system was designed, composed of single-use fluidic 33 
components and a bioreactor housing. The bioreactor was operated using an in-house 34 
developed program and the culture environment was monitored with specifically designed 35 
sensor ports. A gas exchange module was incorporated allowing for heat and mass 36 
transfers. Titanium based scaffolds were seeded with human periosteum derived cells and 37 
cultured for up to 3 weeks. The benchtop bioreactor constructs were compared to 38 
benchmark perfusion systems. Live/Dead stainings, DNA quantifications, glucose 39 
consumption and lactate production assays confirmed that the constructs cultured in the 40 
benchtop bioreactor grew similarly to the benchmark systems. Manual regulation of the 41 
system set-points enabled efficient alteration of the culture environment in terms of 42 
temperature, pH and dissolved oxygen. This study provides the necessary basis for the 43 
development of low-footprint, automated, benchtop perfusion bioreactors and enables the 44 
implementation of active environment control. 45 
  46 
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1 Introduction 47 
The manufacturing of cell based advanced therapy medicinal products (ATMP) requires 48 
technologies that address both scaling and bioprocess challenges [1]. Bioreactors have been 49 
adopted as an enabling technology for ATMP production both for single cell as well as tissue 50 
culture [2; 3]. In contrast to static 2D culture in flasks or cell factories, bioreactors can 51 
incorporate sensors, allowing the identification and control of critical culture parameters 52 
such as temperature, pH, dissolved oxygen (DO) or the fluidic pattern (i.e. perfusion, mixing 53 
or agitation). This enables in-line or online monitoring of cells and their environment, all 54 
within a closed system. In addition, bioreactors have been advocated as cost efficient 55 
platforms, requiring less operator interventions to carry out ATMP manufacturing, while at 56 
the same time providing a low footprint solution for cell culture [4]. Indeed, the footprint is 57 
a major cost driver when these operations are carried out in GMP facilities.  58 
Many dynamic bioreactor systems described in the literature consist of simple perfusion 59 
circuits in which a medium reservoir is linked to a culture vessel via a pump, and the whole 60 
circuit is placed inside an incubator for the control of environmental culture parameters [5; 61 
6; 7; 8]. However, these approaches lack local environmental control and often the 62 
capability to host in-line sensors; this hampers robust production, automated operation as 63 
well as critical process parameter screening and monitoring. In addition, it does not allow 64 
for traceability and quality assurance of the final product. Recent efforts in the field have 65 
been made addressing these concerns, leading to a range of commercially available 66 
bioreactor systems, with environmental control features at different scales and different 67 
modes of operation. However, a high footprint and high cost of goods related to the use of 68 
these systems can impede their wide adoption and use. Table 1 shows a non-exhaustive but 69 
representative overview of existing bioreactor systems for stem cell therapies and tissue 70 
engineering (TE). The commercially available systems were collected based on the 71 
availability of technical specifications while some academic systems highlighting 72 
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environmental monitoring features were selected. All the systems were sorted per cell 73 
culture purpose and per level of environmental monitoring and control. From this table, one 74 
can observe the lack of in-line monitoring and environmental control features for TE 75 
applications. 76 
In the context of patient-specific ATMP manufacturing (autologous approach), the use of 77 
sensor data-driven automated monitoring and control of the bioreactor becomes critical 78 
because of the inherent patient-related variability [10; 11; 12]. In that context, a need for 79 
change in manufacturing and delivery of stem cell ATMPs has been recognized [13]. Unlike 80 
an allogeneic process, in which every run theoretically starts with known, high-quality cells 81 
and predictable process behaviour, the starting material in an autologous process is highly 82 
variable, and might come from individuals with compromised health. The ideal bioreactor 83 
should therefore be able to monitor culture conditions and respond accordingly to assure 84 
that the resulting product has the appropriate critical quality attributes for every single 85 
patient [14]. Regarding the scale of operation, flexibility should be taken into account in the 86 
design of such a bioreactor to allow for adaptability to clinical indications and patient 87 
specific cell growth kinetics. 88 
Altogether, the aforementioned arguments highlight the need for a standalone and 89 
automated bioreactor system with integrated sensors [14]. Such a system could be 90 
beneficial for the clinical translation of point of care (POC) treatments where the low 91 
footprint, automation and standalone capabilities are of significant importance. In this 92 
work, we present a closed bioreactor system whose footprint is significantly lower than 93 
most available systems. Using a non-standalone version of this fluidic (perfusion) set-up, 94 
we have previously reported on the expansion [15], harvest [16] and osteogenic 95 
differentiation of adult progenitor cells [17; 18]. As a proof of concept of the standalone 96 
system’s capabilities, a scaffold-based perfusion culture of human periosteum derived stem 97 
cells (hPDCs) is reported here as a case study. The cells were cultured for up to 21 days in 98 
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the benchtop bioreactor, using automated media exchange while operating independently 99 
from an incubator (benchtop bioreactor system). We compared the outcome with perfusion 100 
rigs operating in incubators (benchmark systems). The objectives of this study were 1) to 101 
compare our benchtop system to the benchmark systems with a case study on the perfusion 102 
culture of human periosteum derived cells (hPDCs), 2) to monitor the culture environment 103 
and 3) to demonstrate its controllability. 104 
2 Materials and methods 105 
2.1 Bioreactor design 106 
An incubator- independent unit was designed to gather all the hardware necessary for cell 107 
culture operations (cell seeding, expansion and tissue maturation) and environment 108 
control. This unit, further referred to as the bioreactor, was composed of three main parts: 109 
the bioreactor housing, the fluidic components and the connecting hardware for computer 110 
control. The frame of the system housing was 3D printed in polyamide and the windows 111 
were plexiglass. The tubing of the circuit was silicone, the feed-through connectors were 112 
polyoxomethylene and the perfusion chambers were machined out of polysulfon. The foot 113 
print of the resulting system was 0.0331m³, approximately one log scale lower than most 114 
other systems (cf. Table 1). In this section, we describe the perfusion circuit and the three 115 
components making up the bioreactor, illustrated of Figure 1. 116 
2.1.1 Perfusion circuit 117 
Figure 1A illustrates a schematic of the bioreactor perfusion circuit. The system is operated 118 
by recirculating the medium from the medium reservoir (❶) to the perfusion chamber 119 
containing the TE construct (❺), while passing by a WMC series 150 peristaltic pump (❷, 120 
operating range: ~0.1 to 70 mL/min), a gas exchange module (❸) and a bubble trap device 121 
(❹), avoiding contact between the cells and air bubbles that could be trapped in the 122 
perfusion line. A sampling line (❻) allows medium removal by controlling pinch valve 3 123 
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(PV3). The circuit can be filled with fresh medium from an external reservoir (❼) using 124 
PV1. 125 
By controlling PV 2, the medium can circulate in another loop bypassing the gas exchange 126 
module, the bubble trap and perfusion chamber. This bypass loop allows perfusing the 127 
circuit at high velocities when filling or sampling medium, while avoiding high shear 128 
stresses to the tissue construct in the perfusion chamber. 129 
The perfusion chamber used in this system, for cell culture, can accommodate a cylindrical 130 
scaffold of around 2 cm in height, and a diameter of 6 mm. However, this bioreactor system 131 
can accommodate a novel design of perfusion chamber where larger or even multiple 132 
constructs can be cultured. 133 
2.1.2 Bioreactor housing 134 
The bioreactor housing encloses all the hardware necessary for the bioreactor operation. A 135 
picture of a prototype is shown in Figure 1G next to the computer that handles process 136 
control, data logging and visualisation. The bioreactor system within its housing is 137 
illustrated in Figure 1E. The housing encloses medium reservoir holders, the peristaltic 138 
pump, the three pinch valves, the gas exchange unit casing and the perfusion chamber 139 
holder. The fluidic components are assembled externally and fixed on these structures 140 
afterwards. An inlet for the controlled gas mixture was added in the housing to access the 141 
gas exchange module casing. 142 
The bioreactor housing also includes all the necessary hardware for environment 143 
monitoring and control, namely: the heating elements, the thermometers and the electronic 144 
and optical connections that allow to bring sensors (O2, pH, temperature) close to the tissue 145 
construct. 146 
Three temperature controllers were included in the housing for a) the reservoir and valves 147 
room (blue area on Figure 1A), b) the perfusion chamber room (red area on Figure 1A) and 148 
c) the gas exchange unit (❸ on Figure 1A). 149 
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2.1.3 Fluidic components 150 
The fluidic components of the systems consist mainly of silicon tubing and Luer connectors 151 
linking the different elements of the perfusion circuit (cfr Section 2.1.1). A picture of the 152 
fluidic components of the main recirculating loop is shown on Figure 1F. Different tubing 153 
sizes were used in the different parts of the circuit. In general, thick tubing (Internal 154 
Diameter (ID) 1.6mm, Outer Diameter (OD) 4.8mm) was preferred in most parts of the 155 
tubing to limit water evaporation through the silicon membrane. Standard tubing (ID 156 
1.6mm, OD 3.2mm) was used in the pinch valve parts and the peristaltic pump. Small tubing 157 
(ID 0.8mm, OD 2.4mm) was used in the gas exchange module to enhance mass and heat 158 
transfers (increased residence time and exchange surface area) while limiting the increase 159 
of medium volume in the circuit. 160 
Luer connectors were used to make connections between the tubing and the reservoirs, the 161 
bubble trap and the perfusion chamber. Specific lids were manufactured for the 162 
recirculation to the medium reservoir while ensuring closing of the system. 163 
It was observed that fluid pressure can increase at different locations of the circuit due to 164 
the numerous connections, junctions and angles in the circuit which could lead to leakages. 165 
Therefore, pressure release points were set at the reservoirs, using Millex®GP filter units 166 
to ensure sterility. The whole single-use fluidic circuits were gas sterilised each time before 167 
use. 168 
2.1.4 Computer control 169 
An in-house developed software code was implemented in MS Visual Studio for the 170 
bioreactor control and the gas mixer control. Figure 1A shows the bioreactor control 171 
software interface and Figures 1B-C-D show the gas mixer interfaces. The software allows 172 
the operator to manually control the various temperature set-points, the perfusion flowrate, 173 
the gas mixture and the gas flowrate. 174 
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In order to optimize the footprint of the system, a connecting metal rack was designed on 175 
which the bioreactor housing could be slid to allow for connection and control via the 176 
computer. This enabled easy handling of the system whilst maintaining flexibility for the 177 
user to disconnect the housing and bring it inside a sterile flow cabinet for operations on 178 
the biological construct. 179 
2.2 Environment monitoring and control 180 
2.2.1 Sensing 181 
Specific sensor ports were designed at the inlet and outlet of the perfusion chamber. These 182 
ports enabled contact between the tip of a sensor and the culture medium, while ensuring 183 
dry sealing of the system and sterility. These sensor tips are depicted on Figures 1H-K. 184 
These sensor ports were designed to be able to host an optical fiber or electrical cable in 185 
order to carry different types of signal (Figure 1K). 186 
A 4600 Model Thermometer (Measurement Specialties®) was adapted at the inlet of the 187 
perfusion chamber to provide continuous monitoring of the temperature of the medium 188 
going to the cells. Over the culture period, the temperature set-points of the bioreactor were 189 
manually regulated to maintain an optimal medium temperature around 37°C. 190 
A SPOT (PreSens®) sensor was placed at the inlet of the perfusion chamber to monitor the 191 
pH of the medium. To demonstrate the ability to externally manipulate the culture 192 
environment, the pH was monitored for a perfusion flow rate of 1mL/min and a medium 193 
temperature stabilized at 37°C, while varying the concentration of CO2 in the gas mixture 194 
from 0% to 30% in steps of 5% (see Figure 2A for result). Such sensor port connections can 195 
also host dO2 sensor (PreSens®, OceanOptics®) or pCO2 sensors (PreSens®). 196 
2.2.2 Evaporation 197 
Evaporation of water out of the culture medium increases the salt concentrations and can 198 
be detrimental to the cultured constructs. Evaporation rates over the circuit were expected 199 
to be the highest in the gas exchange module since it was designed to enhance mass and 200 
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heat transfer. Therefore, a gas humidifier tank was designed to provide a high humidity 201 
environment in the gas exchange module casing. This allowed saturating the air 202 
surrounding the coil tubing and reducing evaporation out of the medium. Since the 203 
operation at a high relative humidity is restricted to the gas exchange module, the other 204 
bioreactor compartments can more easily house any other electronic components.  205 
To verify the efficiency of the humidifier, the evaporation rate of the medium was quantified 206 
by measuring the change in metabolite concentrations over one week of perfusion without 207 
cells. Knowing the baseline metabolite concentrations, the change in concentration can be 208 
correlated to a volume change over time. The lactate and glucose concentrations were 209 
measured with a medium analyzer (Cedex Bio Analyzer®, Roche®) on the bioreactor with 210 
and without humidifier, and compared to benchmark perfusion circuits [19] [15] [20], 211 
running inside a 20% relative humidity (RH) incubator (see Figure 2D for results). 212 
2.3 Bioreactor evaluation and construct growth assessment 213 
In order to demonstrate the use of the bioreactor presented in this study as an in-vitro 214 
culture system for TE constructs, a case study on the perfusion culture of primary cell 215 
seeded scaffolds was performed. 216 
2.3.1 TE constructs 217 
Selective laser melted porous cylindrical Ti6Al4V scaffolds (OD 6mm and 6mm high) were 218 
used as carriers for the TE construct. The production and design details for these scaffolds 219 
were previously described [21]. In order to assure comparability of the results between the 220 
two culture setups, a controllable cell carrier was preferred over a potentially more 221 
biologically relevant carrier. Human PDCs [22], for which approval has been granted by the 222 
Ethical Committee of the University Hospital Leuven (ML7861_S53717), were drop seeded 223 
on the scaffolds (200 000 cells/scaffold) as previously described [15].  224 
The constructs were cultured in both systems for up to three weeks at a perfusion flow rate 225 
of 0.1 mL/min, and the culture medium refreshed every 2-3 days. 226 
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2.3.2 Metabolite levels 227 
Regular sampling of the culture medium was performed for each culture vessel and glucose 228 
and lactate metabolite concentrations were measured. Cumulative glucose consumption 229 
and lactate production profiles were calculated as an indicator of the cell growth dynamics. 230 
Evaporation of water from the culture medium was accounted for when calculating the 231 
production and consumption rates. 232 
2.3.3 Live/Dead staining and DNA measurements 233 
At the end of the culture period, a live/dead viability/cytotoxicity kit (Invitrogen®) was 234 
used to qualitatively evaluate cell viability in the constructs by fluorescent microscopy. The 235 
live/dead staining protocol was performed as previously described [15]. After imaging, 236 
constructs were prepared for DNA quantification using a quantitative and selective DNA 237 
assay (Quant-iTTM dsDNA HS kit, Invitrogen®). Constructs were rinsed in phosphate-238 
buffered saline and the cells lysed in 350µL RLT lysis buffer (with 3.5µL -mercaptoethanol, 239 
Qiagen). DNA was then quantified as previously described [23]. 240 
2.3.4 Quantitative PCR 241 
For all samples, RNA was extracted and quantified using the RNeasy Mini Kit (Qiagen) and 242 
a Nanodrop ND-1000 spectrophotometer (Thermo Scientific), respectively. A RevertAid H 243 
Minus First Strand complementary DNA synthesis kit (Fermentas) was used for synthesis 244 
of complementary DNA and a Sybr green quantitative polymerase chain reaction was 245 
performed for different osteogenic and chondrogenic markers (Sox9, RunX2, Col1, ALP) and 246 
compared to HPRT (HPRT-F, 5’-TGAGGATTTGGAAAGGGTGT-3’; HPRTR, 5’-247 
GAGCACACAGAGGGCTACAA-3’). The PCR reaction was cycled in a StepOnePlus™ PCR 248 
System (Thermo Fisher), as follows: 95°C for 10min, 40 cycles of 95°C for 15 s and 60°C for 249 
60 s. Differences in gene expression were determined relatively in comparison to HPRT and 250 
shown as 2–ΔCT. 251 
2.3.5 Statistical analysis 252 
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An f-test analysis of variance followed by a t-test were performed to quantify significant 253 
differences in gene expression between the two groups, using Microsoft Excel (p=0.05 was 254 
considered significant). 255 
3 Results 256 
3.1 Monitoring and controllability of the environment 257 
An important aspect of the bioreactor system developed in this study, was the environment 258 
control that houses the fluidic components. Its functionality ensures that the fluidic module 259 
is exposed to a controlled environment able to maintain stable conditions or change 260 
according to user demands. Sensor readings are shown on Figure 2A-C which highlights the 261 
monitoring capacity and controllability of the environment. Manual regulation of the 262 
temperature set-points allowed the medium at the inlet of the chamber to be kept close to 263 
37°C (Figure 2C). From the pH readings, the system showed a response time in the range of 264 
1 hour for a perfusion flowrate of 1mL/min. Figure 2A indicates of the sensitivity of the 265 
system to the applied CO2 concentration, enabled by the gas exchange module of the system. 266 
While so far the system displays relevant read outs to the operators for manual regulation 267 
of critical process parameters, no active control was done. However, all the necessary 268 
software and hardware is now set for implementation of active environment regulation. 269 
The evaporation measurements on Figure 2D show the importance of the humidifier to limit 270 
evaporation in the process. The evaporation rate was decreased by 75% using the 271 
humidifier and reached values comparable to the simple systems, running inside 272 
incubators. 273 
3.2 Validation case study 274 
Cell presence and activity within the fluidic circuit was verified and measured using a 275 
number of assays over time. The results of the Live/Dead staining are shown on Figures 2E-276 
J. This figure highlights the living cells (green dye) colonizing the inner space of the scaffold 277 
after three weeks of culture. In both systems, for each run, very small amounts of dead cells 278 
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(red dye) were observed. The cumulative lactate production and glucose consumption 279 
profiles of the constructs are shown on Figures 2K-L. These were calculated relatively to 280 
day 0 of culture (seeding day), when no lactate or glucose had been produced or consumed, 281 
respectively. The DNA content of the constructs at week 3 in the benchtop bioreactor 282 
reached 8.05±2.21µg of DNA (N=3) while constructs cultured in the benchmark systems 283 
reached an amount of 7.00±2.80µg of DNA (N=7) (Figure 2M). 284 
3.3 Gene expression analysis 285 
The results of the relative gene expression levels are shown on Figure 2N-Q. The analyses 286 
revealed no significant differences in the expressions of Sox9 (2.7±0.4 and 2.5±0.5 fold 287 
increase compared to housekeeping gene) and ALP (0.7±0.4 and 0.9±0.2 fold increase) 288 
between the benchtop and the benchmark systems, respectively. Col1 (573.5±67 and 289 
425.8±90.6 fold increase) and RunX2 (3.4±0.8 and 2.3±0.5 fold increase, respectively) were 290 
significantly upregulated in the benchtop bioreactor compared to the benchmark system. 291 
4 Discussion & concluding remarks 292 
Bioreactors are a valuable tool for bringing TE products to the market [24]. However, there 293 
are a certain number of design elements that are required for a successful clinical 294 
translation [25; 26]. These include (I) a closed loop system to assure sterility, (II) use of 295 
biocompatible materials, (III) precise monitoring and control of the 3D cellular 296 
environment, (IV) and integration in GMP production facilities both from a practical and a 297 
regulatory perspective. Additionally, to assure the economic viability of the bioreactor it has 298 
to be able to serve multiple cell therapy and TE applications, which in turn requires a certain 299 
degree of modularity. 300 
The bioreactor design described in this study consists of a housing hosting a closed loop 301 
perfusion circuit. This arrangement ensures no contact between culture medium and 302 
external environment, limiting the risk of contamination. Additionally, a slight overpressure 303 
is created in the housing via the outlet of the gas exchange module, preventing external 304 
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contaminants from entering the system. Whilst during the initial setup of the bioreactor 305 
system it is still required to make sterile connections in a biosafety cabinet, medium 306 
refreshment and sampling during normal operations can be done automatically via the 307 
bioreactor’s user interface.  308 
The materials used for the perfusion system were selected for biocompatibility and 309 
screening experiments were performed in which cells were exposed to media conditioned 310 
with the materials used to verify that there was no cytotoxicity. The data presented here 311 
show that the bioreactor supports long-term growth (up to 3 weeks) of adult progenitor 312 
cells (MSC-like) cells. Indeed, experimental results presented in Section 3.2 indicate that the 313 
cells seeded in the scaffolds and cultured over 3 weeks could proliferate and colonize the 314 
scaffolds similar to the benchtop bioreactor and the benchmark system (cfr Figures 2 E-M).  315 
In both bioreactors, hardly any dead cells were observed at the end of the culture indicating 316 
a viable cell population. Cells were able to bridge pores and grow in 3rd dimension as has 317 
been demonstrated through the use of microCT analysis in previous studies [19].  318 
Metabolite measurements showed cumulative lactate production and glucose consumption 319 
curves of proliferating constructs (Figures 4K-L), with no significant differences between 320 
both vessels. Quantification of DNA (Figure 4M) indicated similar cell yields between the 321 
two operating conditions.  322 
In the context of adult mesenchymal stromal cell types the transcription factors investigated 323 
here can be correlated to the presence of osteo- (RunX2 [27]) and chondro- (Sox9 [28]) 324 
progenitor cell subpopulations and their subsequent respective lineage commitment and 325 
differentiation trajectories. In addition Col1 gene expression is an indicator of early 326 
osteogenesis [29]. There was no difference observed in Sox9 expression while RunX2 was 327 
upregulated in the benchtop bioreactor system. This could suggest a slight commitment to 328 
osteoprogenitor cells also supported by the statistically significant (although small) 329 
upregulation of Col1. However it does not suggest osteogenic differentiation since ALP, a 330 
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later differentiation marker [30], was slightly downregulated. These small gene expression 331 
differences could be also explained by technical differences across the two systems. For 332 
example the flow profile developed due to different pumps would affect the frequency of 333 
pulsatile flow to which the cells were exposed and hence could affect mechanosensitive 334 
genes, such as the ones analyzed here ([29; 31]). Taken together, these data illustrate that 335 
the bioreactor system was capable of supporting scaffold-based 3D progenitor cell cultures. 336 
The bioreactor housing is equipped with multiple (optical) sensor connections and a custom 337 
developed sensor connection was designed, able to bring lab-scale sterilisable in-line 338 
sensors as close as possible to the TE construct in order to monitor and control the 339 
microenvironment of the construct. Additionally, the bioreactor has an integrated incubator 340 
system, which facilitates environmental regulation dynamics (heat and mass transfer) and 341 
therefore increases the environmental control precision but also opens up new possibilities 342 
for model-based control, scalability and increased robustness [32]. 343 
Apart from the environmental control, a custom-made program was developed to visualise 344 
the state of the system, encompassing the environmental parameters and sensor readings 345 
as well as the position of the valves and the remaining volume in the medium reservoir. In 346 
addition, the software centralises these readouts from multiple bioreactor systems running 347 
in parallel. This enables data traceability of the environment and process parameters, as 348 
required for GMP production. 349 
The integrated incubator in the bioreactor also allows for a smaller footprint of the system, 350 
evaluated to a log scale smaller than available systems. Footprint minimization is important 351 
for the integration of the system in manufacturing facilities where space (and especially 352 
incubator space) is a main cost consideration. Moreover, the high humidity environment of 353 
incubators impedes the implementation of advanced sensor systems and electronic 354 
components in the bioreactor housing. The lack of sensor integration in turn makes product 355 
characterisation and comparability of the product (e.g. between multiple production sites) 356 
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and – by extension – the integration of the bioreactor system in a GMP production 357 
environment more challenging. Additionally, the bioreactor housing with three valves, 358 
integrated incubator, multiple sensor connections, a versatile environmental control and 359 
easily controllable peristaltic pump can be equipped with different layouts of the fluidic 360 
systems with differently designed (perfusion) chambers and therefore multiple TE 361 
applications can be targeted. 362 
The use of monitored and controlled bioreactors allows process automation (e.g. automated 363 
liquid transfer steps). Together, these steps serve not only to reduce the cost for patient-364 
specific manufacturing but also to enhance process robustness. In addition, the low 365 
footprint could allow scale-out strategies whereby multiple batches are simultaneously 366 
manufactured, potentially in multiple non-centralized facilities. In the case of individualized 367 
bioprocessing, the production could often aim to take place close to the bedside of the 368 
patient (distributed manufacturing). These versatile and low footprint compact devices 369 
could also be adopted for POC manufacturing within hospital facilities, which could be an 370 
alternative strategy for manufacturing autologous MSC-based ATMPs, in contrast to a more 371 
centralized manufacturing model [4]. 372 
In this work, a novel bioreactor system was presented, having the ability to provide 373 
solutions for automated cell therapy bioprocessing. Such automated, low footprint, closed 374 
systems could support operation outside of clean room environments while minimising 375 
human intervention and therefore providing a cost-effective and less variable alternative to 376 
existing systems. By validating this new culture set up, we demonstrated the feasibility of 377 
TE construct culture in a benchtop and incubator-independent environment. The culture 378 
environment provided by this new system could be monitored and effectively regulated 379 
thanks to the sensors and the operation software. These results go one step further in the 380 
development of more robust systems as the manual labour associated to the handling of 381 
these culture vessels was strongly reduced.  382 
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Table 1. Commercially available bioreactors and reported culture systems in literature for 487 
stem cell therapies and tissue engineering. *The footprint was estimated here from the 488 
space occupied by all the hardware necessary for culture operation, from manufacturer 489 
data, including circuitry (tubing, pump, gas exchangers, bubble trap, cell culture module), 490 
sensors, computers, gas mixer and incubators. The systems annotated with †. require an 491 
external incubator for operation, thus the footprint of a standard incubator was estimated 492 
(Steri-Cult®, Thermo Scientific). **Suitability for Point of Care evaluates the ease of 493 
integration of the culture system in a decentralized manufacturing approach (bedside). N.a.: 494 
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monitoring. 




















~0.5m³ No  Cell expansion 
 Hollow fibre 
Xpansion® Pall Yes ~0.5m³ 
(inc.) 





















Yes ~0.48m³ No  Cell expansion 
 Suspension 
Grayson et al. (1) No ~0.75m³ 
(inc.) 
No  Tissue development 
 Scaffold/fixed-bed 
Talò et al. (2) No ~0.75m³ 
(inc.) 
No  Tissue development 
 Scaffold/fixed-bed 
Schuerlein et al. 
(3) 
Yes ~0.09m³ Potential 
solution 
 Tissue development 
 Scaffold/fixed-bed 
Bhumiratana (4) No ~0.75m³ 
(inc.) 
No  Tissue development 
 Scaffold/fixed-bed 
Volkmer et al. (5) No ~0.75m³ 
(inc.) 
No  Tissue development 
 Scaffold/fixed-bed 
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Figure legends 497 
Figure 1. Presentation of the benchtop bioreactor designed in this study. A: Software 498 
interface for bioreactor control. A scheme of the circuit is drawn (bubble trap ❹ not 499 
included, see F), showing the readings of the several temperature sensors and allowing to 500 
control the perfusion flowrate, the states of the valves and the temperature set-points. Pre-501 
implemented functions allow removing or filling a specific amount of medium with 502 
functional buttons. B: Software interface of the gas mixer, allowing controlling the mixture 503 
of the gas going to the gas-exchange module and the flowrate. C: Real-time graph of the 504 
measured gas flow rates (N2, O2 and CO2) at the output of the gas mixer. D: Real-time graph 505 
of the chosen set-points of the gas mixture. E: Illustration of the bioreactor housing. F: 506 
Picture of a prototype of the bioreactor, highlighting the fluidic components of the 507 
recirculation loop and the internal configuration of the oxygenator. G: Benchtop setup. A 508 
prototype of the bioreactor is shown on the right, next to the computer. H: Perfusion 509 
chamber designed for this study (shown upside down). The white sensor ports are shown. 510 
 22
The blue light (pointed by the yellow arrow) shows the tip of the pH sensor at the inlet of 511 
the chamber. Six sensor ports are available for monitoring at the inlet and the outlet (3 each, 512 
see front view ❺ on A) of the perfusion chamber. I-J: Schematic cuts highlighting how 513 
contact is made between the tip of the sensor ports while maintaining the closure of the 514 
circuit. The red vector shows the perfusion direction. K: Schematic cut of a sensor port, the 515 
different coloured patches show how different sensor types (thermos-resistor, pH, dO2 of 516 
pCO2 sensitive patches) can be adapted. 517 
Figure 2. Comparison of in-vitro culture results and environment modulation results. A: pH 518 
value at the steady state (taken from B after the signal stabilized) as a function of the applied 519 
CO2 concentrations. B: Time series of the pH readings at the inlet of the perfusion chamber 520 
(medium perfused at 1mL/min). The blue and green line respectively show the raw 521 
readings and the Gaussian filtered readings from the sensor (left y-axis). The orange line 522 
shows the time series of the applied CO2 concentrations (right y-axis). C: Temperature 523 
sensor readings at the inlet of the perfusion chamber over a construct culture of 21 days. 524 
The red dash-dotted line shows the optimal objective temperature of 37°C. The sensor 525 
signal was filtered with a Gaussian filter to eliminate artefacts due to regular disconnections 526 
of the bioreactor prototype for medium refreshments. D: Evaporation rates calculated from 527 
metabolites measurements on the basic circuits set inside incubators (white bar), the NBR 528 
with the humidifier tank (black bar) and without (gray bar). E-J: Live/Dead staining results 529 
on TE constructs cultured in the new bioreactor (E-G) and in the basic perfusion circuits (H-530 
J) after 3 weeks at 0.1 mL/min flow rate. The green dye stains the living cells while the red 531 
dye stains the nuclei of the dead cells (scale bars: 1mm, the constructs are 6x6x6 mm). The 532 
red vectors show the direction of the culture medium flow. Top (E, H), side (F, I) and bottom 533 
(G, J) views of the samples are shown. K-L: Cumulative lactate production (mmol, K) and 534 
glucose consumption (mmol, L) of the constructs over the culture time. The empty marker 535 
show average cumulative values for the basic perfusion circuits (N=10), with standard 536 
 23
deviations (black bars). M: DNA content of constructs cultured for 3 weeks at 0.1 mL/min 537 
in the new bioreactor (black, N=3) and in the basic perfusion circuits (white, N=7), error 538 
bars. N-Q: relative mRNA expression levels of Sox9 (N), RunX2 (O), Col1 (P) and ALP (Q) 539 
compared to the housekeeping gene (HPRT). The error bars show the standard deviation 540 
and an asterisk indicates a statistically significant difference (p<0.05). 541 
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